Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone

Diffuse large B-cell lymphoma (DLBCL) is curable in 60% of patients treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP). MYC translocations, with or without BCL2 translocations, have been associated with inferior survival in DLBCL. We investigated whether...

Full description

Saved in:

Bibliographic Details
Published in:	Journal of clinical oncology Vol. 30; no. 28; p. 3452
Main Authors:	Johnson, Nathalie A, Slack, Graham W, Savage, Kerry J, Connors, Joseph M, Ben-Neriah, Susana, Rogic, Sanja, Scott, David W, Tan, King L, Steidl, Christian, Sehn, Laurie H, Chan, Wing C, Iqbal, Javeed, Meyer, Paul N, Lenz, Georg, Wright, George, Rimsza, Lisa M, Valentino, Carlo, Brunhoeber, Patrick, Grogan, Thomas M, Braziel, Rita M, Cook, James R, Tubbs, Raymond R, Weisenburger, Dennis D, Campo, Elias, Rosenwald, Andreas, Ott, German, Delabie, Jan, Holcroft, Christina, Jaffe, Elaine S, Staudt, Louis M, Gascoyne, Randy D
Format:	Journal Article
Language:	English
Published:	United States 01.10.2012
Subjects:	Adolescent Adult Aged Aged, 80 and over Antibodies, Monoclonal, Murine-Derived - therapeutic use Antineoplastic Combined Chemotherapy Protocols - therapeutic use Cyclophosphamide - therapeutic use Disease-Free Survival Doxorubicin - therapeutic use Female Gene Expression Profiling Humans Immunohistochemistry Lymphoma, Large B-Cell, Diffuse - drug therapy Lymphoma, Large B-Cell, Diffuse - genetics Lymphoma, Large B-Cell, Diffuse - mortality Male Middle Aged Prednisone - therapeutic use Prognosis Proto-Oncogene Proteins c-bcl-2 - genetics Proto-Oncogene Proteins c-myc - genetics Rituximab Survival Rate Translocation, Genetic Vincristine - therapeutic use Young Adult
ISSN:	1527-7755, 1527-7755
Online Access:	Get more information
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!